BR112018075434A2 - anticorpo isolado ou fragmento de ligação de antígeno do mesmo, composição farmacêutica, e, métodos para tratar câncer e para modular resposta imune antitumor. - Google Patents

anticorpo isolado ou fragmento de ligação de antígeno do mesmo, composição farmacêutica, e, métodos para tratar câncer e para modular resposta imune antitumor.

Info

Publication number
BR112018075434A2
BR112018075434A2 BR112018075434-0A BR112018075434A BR112018075434A2 BR 112018075434 A2 BR112018075434 A2 BR 112018075434A2 BR 112018075434 A BR112018075434 A BR 112018075434A BR 112018075434 A2 BR112018075434 A2 BR 112018075434A2
Authority
BR
Brazil
Prior art keywords
methods
antigen binding
modulating
pharmaceutical composition
immune response
Prior art date
Application number
BR112018075434-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Delfino Frank
Skokos Dimitris
Wang Bei
Original Assignee
Regeneron Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals, Inc. filed Critical Regeneron Pharmaceuticals, Inc.
Publication of BR112018075434A2 publication Critical patent/BR112018075434A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BR112018075434-0A 2016-06-10 2017-06-09 anticorpo isolado ou fragmento de ligação de antígeno do mesmo, composição farmacêutica, e, métodos para tratar câncer e para modular resposta imune antitumor. BR112018075434A2 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662348353P 2016-06-10 2016-06-10
US62/348353 2016-06-10
US201662432023P 2016-12-09 2016-12-09
US62/432023 2016-12-09
US201762500312P 2017-05-02 2017-05-02
US62/500312 2017-05-02
PCT/US2017/036818 WO2017214548A1 (en) 2016-06-10 2017-06-09 Anti-gitr antibodies and uses thereof

Publications (1)

Publication Number Publication Date
BR112018075434A2 true BR112018075434A2 (pt) 2019-03-19

Family

ID=59078260

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018075434-0A BR112018075434A2 (pt) 2016-06-10 2017-06-09 anticorpo isolado ou fragmento de ligação de antígeno do mesmo, composição farmacêutica, e, métodos para tratar câncer e para modular resposta imune antitumor.

Country Status (19)

Country Link
US (3) US10738126B2 (enExample)
EP (2) EP3468999B1 (enExample)
JP (2) JP7162535B2 (enExample)
KR (1) KR102495601B1 (enExample)
CN (1) CN109563170B (enExample)
AU (1) AU2017278193B9 (enExample)
BR (1) BR112018075434A2 (enExample)
CA (1) CA3027121A1 (enExample)
CL (1) CL2018003515A1 (enExample)
CO (1) CO2018013298A2 (enExample)
IL (1) IL263273B2 (enExample)
MA (1) MA45233A (enExample)
MX (2) MX2018015350A (enExample)
MY (1) MY200162A (enExample)
PH (1) PH12018502502A1 (enExample)
SG (1) SG11201810525XA (enExample)
UA (1) UA128687C2 (enExample)
WO (1) WO2017214548A1 (enExample)
ZA (1) ZA201807920B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR097306A1 (es) 2013-08-20 2016-03-02 Merck Sharp & Dohme Modulación de la inmunidad tumoral
BR112018075434A2 (pt) 2016-06-10 2019-03-19 Regeneron Pharmaceuticals, Inc. anticorpo isolado ou fragmento de ligação de antígeno do mesmo, composição farmacêutica, e, métodos para tratar câncer e para modular resposta imune antitumor.
WO2018071500A1 (en) 2016-10-11 2018-04-19 Agenus Inc. Anti-lag-3 antibodies and methods of use thereof
WO2018107178A1 (en) 2016-12-09 2018-06-14 Regeneron Pharmaceuticals, Inc. Systems and methods for sequencing t cell receptors and uses thereof
CR20200466A (es) * 2018-03-13 2020-11-11 Tusk Therapeutics Ltd Agentes anticuerpos anti-cd25
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
WO2020167919A1 (en) 2019-02-12 2020-08-20 Regeneron Pharmaceuticals, Inc. Compositions and methods for using bispecific antibodies to bind complement and a target antigen
RU2734432C1 (ru) 2019-04-23 2020-10-16 Закрытое Акционерное Общество "Биокад" Моноклональное антитело, которое специфически связывается с GITR
US20230064703A1 (en) * 2020-01-02 2023-03-02 Nanjing GenScript Biotech Co., Ltd. Anti-gitr antibodies and uses thereof
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
AU2021232041A1 (en) 2020-03-06 2022-09-08 Regeneron Pharmaceuticals, Inc. Anti-GITR antibodies and uses thereof
WO2022148279A1 (zh) * 2021-01-08 2022-07-14 苏州丁孚靶点生物技术有限公司 药物产品及其用途
WO2022150654A2 (en) * 2021-01-08 2022-07-14 10X Genomics, Inc. Antigen-binding polypeptides specific for coronaviruses and uses thereof
KR102475255B1 (ko) * 2021-05-10 2022-12-09 메디맵바이오 주식회사 항-gitr 항체 및 이의 용도
AU2023235594A1 (en) 2022-03-15 2024-09-12 Yeda Research And Development Co. Ltd. Anti glucocorticoid-induced tnfr-related (gitr) protein antibodies and uses thereof

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
EP1947183B1 (en) 1996-08-16 2013-07-17 Merck Sharp & Dohme Corp. Mammalian cell surface antigens; related reagents
US6111090A (en) 1996-08-16 2000-08-29 Schering Corporation Mammalian cell surface antigens; related reagents
US6689607B2 (en) 1997-10-21 2004-02-10 Human Genome Sciences, Inc. Human tumor, necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2
US6503184B1 (en) 1997-10-21 2003-01-07 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2
ATE419357T1 (de) 1997-11-18 2009-01-15 Genentech Inc Dna 19355 polypeptide, ein homolog des tumornekrosefaktors
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
EP1462114A1 (en) 2003-03-28 2004-09-29 Universiteit Utrecht Holding B.V. Methods and means to suppress symptons of an allergic disease by inhibiting the glucocorticoid-induced tumor necrosis factor receptor (GRIT or TNFRSF18)
MXPA05012475A (es) 2003-05-23 2006-05-25 Wyeth Corp Anticuerpos y moleculas relacionadas con el ligando para el receptor tnf inducido por glucorticoides (gitr) y el ligando (gitr) y usos de los mismos.
US20060099171A1 (en) 2004-11-05 2006-05-11 Masahide Tone Mouse glucocorticoid-induced TNF receptor ligand is costimulatory for T cells
DK1866339T3 (da) 2005-03-25 2013-09-02 Gitr Inc GTR-bindende molekyler og anvendelser heraf
US20110212086A1 (en) 2006-01-19 2011-09-01 Genzyme Corporation GITR Antibodies For The Treatment of Cancer
WO2007084775A2 (en) 2006-01-20 2007-07-26 The Trustees Of The University Of Pennsylvania Compositions and methods for modulation of suppressor t cell activation
NZ573557A (en) 2006-06-02 2010-08-27 Regeneron Pharma High affinity antibodies to human il-6 receptor
NO347649B1 (no) 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
ES2776406T3 (es) 2007-07-12 2020-07-30 Gitr Inc Terapias de combinación que emplean moléculas de enlazamiento a GITR
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
US8709424B2 (en) 2009-09-03 2014-04-29 Merck Sharp & Dohme Corp. Anti-GITR antibodies
US20130108641A1 (en) 2011-09-14 2013-05-02 Sanofi Anti-gitr antibodies
JP6053688B2 (ja) 2011-10-07 2016-12-27 国立大学法人三重大学 キメラ抗原受容体
KR101566539B1 (ko) 2012-06-08 2015-11-05 국립암센터 신규한 Ｔｈ2 세포 전환용 에피토프 및 이의 용도
AR097306A1 (es) * 2013-08-20 2016-03-02 Merck Sharp & Dohme Modulación de la inmunidad tumoral
TW201605896A (zh) 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
PL3148579T3 (pl) 2014-05-28 2021-07-19 Agenus Inc. Przeciwciała anty-gitr i sposoby ich zastosowania
PL3151921T3 (pl) 2014-06-06 2020-02-28 Bristol-Myers Squibb Company Przeciwciała przeciwko receptorowi indukowanego glukokortykoidami czynnika martwicy nowotworu (gitr) i ich zastosowania
JP2017531427A (ja) 2014-10-03 2017-10-26 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド グルココルチコイド誘導腫瘍壊死因子受容体（ｇｉｔｒ）抗体およびその使用法
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
AU2015338974B2 (en) * 2014-10-31 2021-08-26 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of disease
BR112018075434A2 (pt) 2016-06-10 2019-03-19 Regeneron Pharmaceuticals, Inc. anticorpo isolado ou fragmento de ligação de antígeno do mesmo, composição farmacêutica, e, métodos para tratar câncer e para modular resposta imune antitumor.

Also Published As

Publication number Publication date
MX2022014695A (es) 2022-12-16
EP4344748A3 (en) 2024-06-12
MX2018015350A (es) 2019-08-26
CO2018013298A2 (es) 2019-02-19
US20230042324A1 (en) 2023-02-09
UA128687C2 (uk) 2024-10-02
SG11201810525XA (en) 2018-12-28
JP2019521098A (ja) 2019-07-25
KR102495601B1 (ko) 2023-02-06
IL263273B1 (en) 2025-06-01
MY200162A (en) 2023-12-09
JP2022159476A (ja) 2022-10-17
US20210147565A1 (en) 2021-05-20
EP4344748A2 (en) 2024-04-03
CN109563170B (zh) 2023-10-13
US10738126B2 (en) 2020-08-11
ZA201807920B (en) 2024-01-31
CN109563170A (zh) 2019-04-02
EP3468999A1 (en) 2019-04-17
AU2017278193B9 (en) 2024-02-01
AU2017278193B2 (en) 2024-01-18
KR20190020297A (ko) 2019-02-28
US11414494B2 (en) 2022-08-16
WO2017214548A1 (en) 2017-12-14
AU2017278193A1 (en) 2018-12-13
MA45233A (fr) 2019-04-17
CL2018003515A1 (es) 2019-03-08
IL263273A (en) 2018-12-31
CA3027121A1 (en) 2017-12-14
IL263273B2 (en) 2025-10-01
PH12018502502A1 (en) 2019-04-08
JP7162535B2 (ja) 2022-10-28
NZ748619A (en) 2024-05-31
US20170355774A1 (en) 2017-12-14
EP3468999B1 (en) 2024-01-10

Similar Documents

Publication Publication Date Title
BR112018075434A2 (pt) anticorpo isolado ou fragmento de ligação de antígeno do mesmo, composição farmacêutica, e, métodos para tratar câncer e para modular resposta imune antitumor.
CY1124791T1 (el) Μορια δεσμευσης ειδικα για cd73 και χρησεις αυτων
PH12019500270A1 (en) Combination therapy for cancer
ZA202308021B (en) Anti-ctla4 antibodies and methods of making and using the same
PH12016501549A1 (en) Tergeted tgf� inhibition
CL2020003071A1 (es) Proteínas de unión multiespecíficas y mejoras con estas
BR112019010595A2 (pt) anticorpo ou fragmento de ligação ao antígeno do mesmo, combinação de moléculas de ácido nucleico isoladas, composição farmacêutica, kit, e, método para selecionar um composto.
BR112018010172A2 (pt) anticorpos contra receptor de fator de necrose de tumor induzido por glicocorticoide (gitr) e usos dos mesmos
CL2019002144A1 (es) Conjugados de fármacos y anticuerpos anti–ccr7.
BR112016016207A2 (pt) Anticorpo anti-pd-l1 isolado ou fragmento de ligação ao antígeno do mesmo, seu método de produção, composição farmacêutica, molécula de polinucleotídeo isolada, vetor, célula, e uso dos mesmos
BR112016030686A2 (pt) anticorpos anti tau humanizados
BR112016028378A2 (pt) anticorpos contra o receptor do fator de necrose tumoral induzido por glicocorticoide (gitr) e usos dos mesmos
UY36536A (es) Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123
MX377844B (es) Anticuerpos anti proteína relacionada con el receptor del factor de necrosis tumoral inducida por glucocorticóides (gitr) y sus métodos de uso.
BR112016009797A2 (pt) anticorpos específicos de ligante 1a do tipo fator de necrose tumoral e composições e usos dos mesmos
EA201791050A1 (ru) Конъюгаты антител и лекарственных средств
CY1123781T1 (el) Anti-tnf αλφα-αντισωματα και λειτουργικα θραυσματα αυτων
BR112019005129A2 (pt) anticorpos anti-pd-1
BR112017021484A2 (pt) anticorpos de direcionamento à proteína morfogenética óssea 9 (bmp9) e métodos para os mesmos
CY1123784T1 (el) Αντισωματα enanti-tnf αλφα και λειτουργικα θραυσματα αυτων
BR112018072118A2 (pt) anticorpos de interferona beta e usos dos mesmos
BR112021016791A2 (pt) Proteínas de ligação de antígenos que se ligam a bcma
BR112021026309A2 (pt) Anticorpos para ativação de células t
MX2024003627A (es) Anticuerpos contra el receptor del factor de necrosis tumoral inducido por glucocorticoides (gitr) y sus metodos de uso.
EA201892090A1 (ru) АНТИТЕЛА К ФНО-α И ИХ ФУНКЦИОНАЛЬНЫЕ ФРАГМЕНТЫ

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]